ClinicalTrials.gg
RecruitingNCT05861297Updated May 16, 2023

Immune Thrombocytopenia Management in Adults

A Phase 4 interventional study of Dexamethasone and Prednisolone and Azathioprine in Immune Thrombocytopenia Purpura, sponsored by Nahda University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Nahda University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 11 months after the study started (first participant enrolled May 2020, registered Apr 2023).
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
467
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Egypt.

Planned enrollment
Largest of 13
467 · median 80
Started
2020
with 1 other
Phase 4
3 of 17
1 open now
Registered
11th of 17
by date
Lead sponsor
1 of 17
Nahda University

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Egypt, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2020, is one of 3 in phase 4, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

6 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic with a site in Egypt, or all of them as a file.
02

Study summary

Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only benefits without drawbacks. This study compares the clinical outcomes and adverse drug patterns of different treatment options. Medications which will be assessed during the current study are High Dose-dexamethasone (HD-DXM) (control group), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim.

Read the detailed description

A prospective controlled randomized study was conducted on primary Immune thrombocytopenia patients. The study's main objective is to evaluate the efficacy and adverse events profile of the different therapeutic approaches during Immune thrombocytopenia. Upon the confirmation of the Immune thrombocytopenia diagnosis, all patients immediately initiated the High Dose-dexamethasone as a frontline therapy for Immune thrombocytopenia with a dose of 40 mg/m2 daily for 4 days/week in the first month for one cycle. Then, the recruited patients who fulfilled the inclusion criteria are randomly assigned into one of five groups. Among these patients, the control group received IV pulse (HD-DXM) therapy with 40 mg/m2 daily for 4 successive days in a 28-day cycle to complete the six cycles. The Prednisolone + Azathioprine group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months. The Rituximab group received 500 mg/m2 intravenously of Rituximab once weekly for one month. The Eltrombopag group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months. The Romiplostim group received 3μg/kg sub-cutaneous injection of Romiplostim once a week for 6 months. The first evaluation date of confirmed ITP diagnosis was well-defined as the first index date (baseline). After that, every patient visited the investigational site as the protocol prescribes once weekly to assess and adjust the doses of study medications. The outcome measures were judged at baseline, at the end of treatment (6 months), and after an additional 6-month free treatment period.

03

Conditions studied

  • Immune Thrombocytopenia Purpura

Keywords

  • Primary Immune Thrombocytopenia
  • Etrombopag
  • Dexamethasone
  • Romiplostim
  • Rituximab
  • Autoimmune Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria were adult patients aged 18 years or older, diagnosed with primary ITP after excluding secondary causes and with an initial PLTs count of less than 30 ×109/L or with hemorrhage manifestations.

Exclusion criteria

Exclusion Criteria:

  • Patients with a confirmed secondary ITP diagnoses such as (chemicals induced, systemic lupus erythematosus, immune thyroid diseases, a lymphoproliferative disease, or chronic infection, such as Helicobacter pylori, (HIV) or virus (HCV); with cardiac, renal, or liver disease; who had received NSAIDs or anti- within one month before the initiation of the enrollment were excluded from the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
467 participants (estimated)

Study arms

  • Active comparator
    Control group

    The first (control )group includes patients with confirmed diagnosed who received IV pulse (High Dose-Dexamethasone) therapy

    Drug: Dexamethasone

  • Experimental
    PSL - AZA group

    The second group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy

    Drug: Prednisolone and Azathioprine

  • Experimental
    The RTX group

    The third group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy

    Drug: Rituximab

  • Experimental
    The ELTRO group

    The fourth group includes patients with confirmed diagnosed who received E therapy

    Drug: Eltrombopag

  • Experimental
    The ROMP group

    The fifth group includes patients with confirmed diagnosed who received Romiplostim therapy

    Drug: Romiplostim

Interventions

  • Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months

  • DrugPrednisolone and Azathioprine

    Drug pages: PrednisoloneStudies of PrednisolonePrednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AzathioprineStudies of AzathioprineAzathioprine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.

  • The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month

  • The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months

  • The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months

06

What researchers measure

Primary outcomes

  1. total patients who achieved sustained and overall response

    The primary outcomes were the total percentage of patients achieving a sustained response (SR) till the end of the study, complete response (CR), and partial response (PR). CR was characterized by the absence of bleeding and an increase in the platelet count to above 100×109/L after one month of the treatment. SR was defined as achieving CR or partial response (PR) until the end of the study with a 2-fold upsurge from starting point \[20, 21\]. PR was represented as PLTs count ≥ 30×109/L after one month following therapy, and no response (NR) was defined as platelets \< 30×109/L or bleeding

    Time frame: 18 months

Secondary outcomes

  1. number of patients relapsed and adverse events

    The secondary outcome measures were a number of patients relapsed and adverse events (AEs). Relapse was pointed out as PLTs count below 30×109/L or bleeding episodes owing to thrombocytopenia afterward achieving the CR

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Jan 2024, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2023
First posted
May 16, 2023
StartActual
May 5, 2020
Primary completionEst.
Jan 18, 2024
CompletionEst.
Apr 2, 2024
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05861297
Lead sponsor
Nahda University
Responsible party
Eman Mostafa Hamed (Teaching Assistant clinical pharmacy department, faculty of pharmacy, Nahda University) — Principal investigator
First posted
May 16, 2023
Start date
May 5, 2020
Primary completion
Jan 18, 2024 (estimated)
Completion
Apr 2, 2024 (estimated)
Last update
May 16, 2023

Study contacts

Eman Mostafa Hamed, master
Contact
eman.hamed@nub.edu.eg
01019834193
Mostafa Hamed
Contact
eman.hamed@nub.edu.eg
01286744337
Mohamed Hussein Meabed, professor
study chair · faculty of medicine beni-suef university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisolone · Azathioprine · Rituximab · Eltrombopag · Romiplostim

Start the discussion